Replies to post #7220 on RespireRx Pharmaceuticals Inc (fka RSPI)

[Aiming4]

Bladerunner - you touched on several recurring thoughts I have about Cortex.

It still amazes me that sheer size of the markets that Ampakines may eventually be approved for, combined with the lean pipelines of many BPs, doesn't result in competitive bidding for Cortex's deals and doesn't result in much higher valuations being discussed for those deals.

Perhaps both of those situations have already changed unbeknown to us yet, or will have changed when the deal making process finally plays out and shows competitive interest driving the deal prices up.

But for now it seems that no one is expecting any kind of eyebrow raising deal for either CX717 or the high impacts.

It will be ironic if Cortex gets a better deal for CX717 now vs. 15 months ago - but a year plus of patent life has also been lost. The eventual lost revenue cost for that year of patent life could be huge.

Cortex's stock price misadventures have allowed me to now hold many more shares of COR than I ever expected to hold - and I'm guessing that's true for a lot of the readers/posters on this board.

Those who followed the company closely last year had several good opportunities to sell COR knowing it had a good chance of dropping lower.

Then came the CC where Dr. Stoll showed clear confidence that the FDA finding was caused by the fixative, and that provided a golden opportunity for those closely watching COR to jump back in.

So... the irony of the FDA hold and dosage restrictions possibly helping Cortex with a much higher deal valuation also extends to all of the COR longs who now hold more shares than before and at lower average prices.

Both life and biotech investing are a series of improbable twists and turns.

[money4retirement]

yes, it certainly would be, and it's a good possibility, as you point out, based on the other deals being made.

what seems low to me is the $8 pps post partnership deal that's been estimated as of late, if (we all know what the "if" is). and while i would be happy to get to $8 because that would mean the "if" finally happened (and $8 is a lot better than $2.65). we were at 6$ pre-fda approval a little over a year ago, with fda approval and with the extensive additional testing on cx717 (as someone stated, and i agree, that makes the chances of a problems arising much less and adds value), those two things i'm guessing will get us to a pps of $8. then a good partnership in light of other deals, i'm guessing will get us to a pps of $12.

if i remember correctly, i think "neuro" pre fda hold had a $12 price target on cor. i don't see why the current pps estimate should be less "if" the fda gives cor the green light..

of course this comes from someone who has 100% invested in COR.
i hope we don't have to wait much longer for the fda decision.

good luck to cor shareholders.

fred

[Market_Fest4]

Blade,
I agree. $30M is enough to keep the doors open for 2 more years. Hardly an amount to get excited about.

MF4